Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

In this study, a 68-year-old man with muscle-invasive bladder cancer and renal insufficiency achieved a partial radiological response to neoadjuvant therapy with gemcitabine and Disitamab Vedotin, without significant adverse events, highlighting a potential alternative for cisplatin-ineligible patients.

This case report highlights the successful treatment of a 37-year-old male with steroid-resistant beard alopecia areata using baricitinib, a JAK-1/2 inhibitor, over 9 months, resulting in reduced hair loss and improved hair density.

This study found that mitotane causes specific changes in cortisol metabolism, including increased excretion of certain metabolites, which may influence cortisol bioavailability without hindering early detection of adrenocortical carcinoma recurrence.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

This research focused on understanding how radiotherapy affects mitochondrial function and signaling pathways in metastatic breast cancer cells, aiming to clarify its roles in cell survival, apoptosis, and metastatic progression, but the results are not reported in the abstract.

This study found that 86% of patients with follicular non-Hodgkin's lymphoma were alive and nearly two-thirds remained in complete remission eight years after initial treatment with the radioimmunotherapy drug Bexxar.

This study found that METTL1 is upregulated in papillary thyroid cancer tissues and promotes cancer cell proliferation and metastasis through its tRNA methyltransferase activity.

This study found that tofacitinib and baricitinib had an acceptable adverse reaction profile when used to treat rheumatoid arthritis, with similar side effects to those described in their technical data sheets.

This study found that the BIK1 gene in Arabidopsis thaliana modulates defense responses to pathogens and is essential for normal root growth and development.

In this study, the researchers reported that baricitinib improved hair loss in a real-world setting for Japanese adults with alopecia areata, with a 64.7% success rate at 60 weeks, though prolonged episodes reduced efficacy. Common side effects were acne and mildly decreased renal function.

This study found that MAP-2 is intensely expressed in the companion layer of the hair follicle, suggesting its potential importance to follicle integrity and possible involvement in some types of alopecia.

In this institution-based randomized trial, oral betamethasone mini-pulse therapy for alopecia areata showed a faster therapeutic response compared to oral tofacitinib, as measured by trichoscopic changes and achievement of 50% hair regrowth.

This study isolated a bioactive peptide from Trapa japonica fruit and found that it may protect human dermal papilla cells from DHT-induced stress, suggesting potential for biomedical applications.

In this pilot study, both tofacitinib and methotrexate improved alopecia areata outcomes, but tofacitinib showed greater efficacy in achieving significant SALT score improvement after 6 months, although the difference was not statistically significant.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

This article reviews Frambusia, a skin-contact-spread tropical infection, and stresses improving medical professionals' diagnostic and treatment skills to achieve the WHO's eradication target by 2030, without reporting new results.

In this retrospective study at Hiroshima University, methotrexate effectively controlled ocular inflammation in Japanese patients with non-infectious uveitis over 6 to 24 months, but a high incidence of adverse effects indicates careful monitoring and dose adjustments are important.

This study engineered a programmable platform using miniaturized needle arrays for drug delivery, showing improved wound healing outcomes in diabetic mice compared to standard topical treatments.

This study found that mushroom beta-glucans combined with radiation therapy may help control tumor growth and reduce metastasis in mice with Lewis lung carcinoma.

This study developed a simple method to determine finasteride, indapamide, and tiemonium methylsulfate in pharmaceuticals by using their ability to form silver nanoparticles measurable via spectrophotometry.

In this case report, a young adult male with resistant alopecia areata showed nearly 90% hair regrowth after 3 months of treatment with tofacitinib, alongside biotin supplementation, without any side effects observed.

This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.

This phase I study found that MK-2206 was well tolerated and demonstrated evidence of AKT signaling blockade in patients with advanced solid tumors, with the maximum-tolerated dose established at 60 mg.

This study optimized a screening assay to identify molecules that inhibit or enhance TRPM5 ion channel activity, which may have implications for treating dysfunctions linked to cardiac arrhythmias and diabetes.